Key statistics
On Monday, Vanda Pharmaceuticals Inc (VM4:FRA) closed at 6.55, -13.82% below its 52-week high of 7.60, set on Jan 02, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.55 |
|---|---|
| High | 6.55 |
| Low | 6.55 |
| Bid | -- |
| Offer | -- |
| Previous close | 6.00 |
| Average volume | 162.60 |
|---|---|
| Shares outstanding | 59.10m |
| Free float | 54.84m |
| P/E (TTM) | -- |
| Market cap | 447.36m USD |
| EPS (TTM) | -1.43 USD |
Data delayed at least 15 minutes, as of Feb 09 2026 07:23 GMT.
More ▼
Press releases
- Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
- Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
- Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
- Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
- FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
- Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
More ▼
